Search


PDF Archive search engine
Last database update: 25 February at 08:43 - Around 75000 files indexed.


Show results per page

Results for «paclitaxel»:


Total: 6 results - 0.02 seconds

v15n4S 57Revisiting 100%

The use of bevacizumab in combination with paclitaxel as first-line therapy for human epidermal growth factor receptor-2–negative metastatic breast cancer has been approved in more than 80 countries worldwide, including Hong Kong, Australia, the European Union, Korea, Malaysia, New Zealand, Switzerland, and Taiwan.

https://www.pdf-archive.com/2019/04/11/v15n4s57revisiting/

11/04/2019 www.pdf-archive.com

Luca Gianni 97%

 Gianni  has  been  involved  in  the  development  of  paclitaxel  in  ovarian  and  breast  cancer.

https://www.pdf-archive.com/2016/08/12/luca-gianni/

12/08/2016 www.pdf-archive.com

CV 86%

therapeutic implication NEW IDEA AWARD 2008 REGINA ELENA CANCER INSTITUTE (PI) - Exploratory Biomarkers study of phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy ASTRAZENECA 2009 (PI) Trials Clinici Principale Ricercatore Traslazionale Dr.ssa Anna Bagnato “A phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of ZD4054 plus Carboplatin and Paclitaxel or Placebo plus Carboplatin and Paclitaxel in Patients with Advanced Ovarian Cancer Sensitive to Platinumbased Chemotherapy” BIBLIOGRAFIA Castelli M., Guadagni S., Bagnato A., Pistoia M.A., Carboni M., Sega E.

https://www.pdf-archive.com/2017/09/14/cv/

14/09/2017 www.pdf-archive.com

eNERGY Protocole signe V2.0 2017.11.06 71%

40 • Carboplatin-paclitaxel ...................................................................................................................

https://www.pdf-archive.com/2017/11/14/energy-protocole-signe-v2-0-2017-11-06/

14/11/2017 www.pdf-archive.com

eNERGY NoteInfoConsentement V2.0 2017.11.06 47%

paclitaxel (90 mg/m2) avec carboplatine (AUC 6) avec une dose qui sera limitée à 700 mg, pendant 4 à 6 heures au Jour 1 de chaque cycle, puis paclitaxel (90/mg/m²) au Jour 8 et au Jour 15 de chaque cycle de 4 semaines, OU pemetrexed (500mg/m2) avec carboplatine (AUC 5) avec une dose qui sera limitée à 700 mg, pendant 4 à 6 heures au Jour 1 de chaque cycle de 3 semaines, Si votre maladie répond favorablement après 4 cycles de pemetrexed + carboplatine, le médecin-investigateur pourra vous proposer de poursuivre le pemetrexed seul, en cycles de 3 semaines, sans limite de durée tant que la maladie est contrôlée et que vous supportez bien ce traitement.

https://www.pdf-archive.com/2017/11/14/energy-noteinfoconsentement-v2-0-2017-11-06/

14/11/2017 www.pdf-archive.com

2016.01.04 08-10-48Reena Nair cv 2016 41%

Multicentre Study of a Cremophor ® - Free, Protein Stabilized, Nanoparticle Formulation of Paclitaxel (ABI-007) in-Patients with Stage IV Metastatic Breast Cancer’ sponsored by Quintiles Spectral (I) Ltd.

https://www.pdf-archive.com/2018/09/11/2016010408-10-48reena-nair-cv-2016/

11/09/2018 www.pdf-archive.com